US › Healthcare

Atea Pharmaceuticals Inc (AVIR)

US · Healthcare · Biotechnology

$4.32-4.64%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-32.9M

EPS

$-0.41

EPS estimate

$-0.56

EPS came in at -0.41 against a street estimate of -0.56 — a beat of 26.8%.

Key statistics

Market cap

$399.4M

Forward P/E

0.0

P/B

2.08

Book value

$2.54

EPS (TTM)

$-2.09

52-week high

$6.45

52-week low

$2.87

50-day MA

$5.25

200-day MA

$4.87

Beta

0.39

Analyst view

Analysts rate Atea Pharmaceuticals Inc a buy (2 buy, 1 hold, 0 sell out of 3) with an average price target of $9.42.

Shareholding

Insiders

13.37%

Institutions

79.20%

Largest institutional holders

Fund	Stake
FMR Inc	14.97%
BlackRock Inc	10.87%
BML Capital Management LLC	8.67%
TANG CAPITAL MANAGEMENT LLC	6.00%
Vanguard Capital Management, LLC	3.70%
Bain Capital Life Sciences Investors, LLC	2.59%
Acadian Asset Management LLC	2.54%
Geode Capital Management, LLC	2.44%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Atea Pharmaceuticals Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.